AFP and hepatocellular carcinoma: The diagnostic accuracy of each biomarker separately was moderate for BCLC‐0/A (AUROC 65.8% for AFP and 65% for PIVKA‐II), higher in BCLC‐B HCC patients and especially for AFP (AUROC 86.4% for AFP and 79.5% for PIVKA‐II) and quite high (AUROC above 90%) among BCLC‐C stage HCC patients (AFP: AUROC = 94.3%, best proposed cutoff value = 12.35 ng/mL and PIVKA‐II: AUROC = 91.3%, best proposed cutoff value = 253.51 mAU/mL), as shown in Figure 2.